This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Precision BioSciences (DTIL) Stock Moves -1.32%: What You Should Know
by Zacks Equity Research
Precision BioSciences (DTIL) closed at $3.75 in the latest trading session, marking a -1.32% move from the prior day.
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 41.86% and 6.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Precision BioSciences (DTIL) closed at $4.28 in the latest trading session, marking a -1.83% move from the prior day.
Moderna (MRNA) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 14.85% and 7.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
What to Expect From Precision BioSciences (DTIL) Q4 Earnings
by Zacks Equity Research
On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.
Precision BioSciences (DTIL) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Precision BioSciences (DTIL) closed the most recent trading day at $4.82, moving -0.62% from the previous trading session.
Precision BioSciences (DTIL) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Precision BioSciences (DTIL) closed at $4.86, marking a +0.83% move from the previous day.
Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD
by Zacks Equity Research
Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.
Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies
by Zacks Equity Research
Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.
Horizon (HZNP) Submits sBLA for Krystexxa Label Expansion
by Zacks Equity Research
Horizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout.
Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt
by Zacks Equity Research
Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.
Lilly (LLY) Inks Deal for Multiple Neurologic Indications
by Zacks Equity Research
Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.
Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics
by Zacks Equity Research
Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.
Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis
by Zacks Equity Research
Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.
Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition
by Zacks Equity Research
While Intellia's (NTLA) pipeline is in early-stage clinical studies, its development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.
Can-Fite (CANF) Files Patent Applications for Namodenoson
by Zacks Equity Research
Can-Fite (CANF) files patent applications in several countries for treating all advanced solid tumors. The filing comes after Can-Fite's drug cleared all tumor lesions in advanced liver cancer.
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
by Zacks Equity Research
Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.
ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA
by Zacks Equity Research
ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis. Shares rise.
Bellus (BLU) Stock Surges on Data From Chronic Cough Study
by Zacks Equity Research
Bellus Health (BLU) achieves the primary endpoint in a phase IIb study evaluating BLU-5937 for the treatment of refractory chronic cough.
Intellia (NTLA) Begins Dosing in Hereditary Angioedema Study
by Zacks Equity Research
Intellia (NTLA) doses the first patient in a phase I/II study to evaluate NTLA-2002 as a single-dose therapy for preventing attacks in patients having hereditary angioedema.
SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.
Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021
by Zacks Equity Research
Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint.
Heron's (HRTX) Zynrelef Gets FDA Nod for Label Expansion
by Zacks Equity Research
The FDA grants label expansion to Heron???s (HRTX) Zynrelef for pain relief after small to medium abdominal surgeries, lower extremity total joint replacements, and foot and ankle surgeries in adults.
Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq
by Zacks Equity Research
Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.
Bayer's (BAYRY) Phase III Study on Nubeqa Combo Meets Goal
by Zacks Equity Research
Bayer's (BAYRY) phase III study evaluating Nubeqa in combination with docetaxel and androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer meets the primary endpoint.